文献速递心力衰竭与心肌病

疑似心力衰竭患者按NICE指南转诊后的特征与结局

Characteristics and outcomes of patients with suspected heart failure referred in line with National Institute for Health and Care Excellence guidance.
PubMed 文献 · Heart · 2020-07-20

这项回顾性多中心观察性研究纳入2014-2016年英国初级保健按NICE指南转诊的1271例疑似心衰且NTproBNP升高患者,中位年龄80岁,55%确诊心衰;1年死亡10%、住院33%;2周路径患者死亡和住院率高于6周路径。

要点

  • 按NICE指南转诊的疑似心衰患者以高龄为主,确诊心衰比例达55%。
  • 2周路径患者1年死亡14%、住院38%,均显著高于6周路径的6%和27%。
  • 无论是否确诊心衰,1年死亡和住院率均较高且无显著差异。

核心结论

  • 按NICE短等待时间目标转诊疑似心衰且NTproBNP升高患者,可识别出高龄且心衰比例高的人群,无论诊断如何不良结局均高。

研究设计与样本

  • 回顾性、多中心、观察性研究,连续纳入2014-2016年从初级保健按NICE 2周和6周路径转诊至二级护理心衰门诊的疑似心衰患者1271例。

主要发现

  • 中位年龄80岁(IQR 73-85),女性680例(53%)。
  • 667例(53%)经2周路径转诊,604例(47%)经6周路径转诊。
  • 698例(55%)确诊心衰,其中369例为射血分数降低的心衰;566例(45%)未确诊心衰。
  • 1年死亡129例(10%),住院413例(33%)。
  • 2周路径较6周路径1年死亡率更高(14% vs 6%,p<0.001),住院率更高(38% vs 27%,p<0.001)。

关键数值与推荐

  • NICE推荐疑似心衰且NTproBNP升高患者转诊专科评估和超声心动图。
  • NTproBNP>2000 pg/mL者应在2周内就诊(2周路径)。
  • NTproBNP 400-2000 pg/mL者应在6周内就诊(6周路径)。

临床怎么用

  • 临床可参照NICE路径依据NTproBNP水平对疑似心衰患者进行快速分层转诊。
  • 对按此路径转诊的高龄患者,无论最终是否确诊心衰,均应关注其高死亡和住院风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the population, heart failure (HF) diagnosis rate, and 1-year hospitalisation and mortality of patients with suspected HF and elevated N-terminal pro B-type natriuretic peptide (NTproBNP) investigated according to UK National Institute for Health and Care Excellence (NICE) guidelines. METHODS: NICE recommends patients with suspected HF, based on clinical presentation and elevated NTproBNP, are referred for specialist assessment and echocardiography. Patients should be seen within 2 weeks when NTproBNP is >2000 pg/mL (2-week pathway: 2WP) or within 6 weeks when NTproBNP is 400-2000 pg/mL (6-week pathway: 6WP). This is a retrospective, multicentre, observational study of consecutive patients with suspected HF referred from primary care between 2014 and 2016 to dedicated secondary care HF clinics based on the NICE 2WP and 6WP. Data were obtained from hospital records and episode statistics. Mortality and hospitalisation rates were calculated 1 year from NTproBNP measurement. RESULTS: 1271 patients (median age 80; IQR 73-85) were assessed, 680 (53%) of whom were female. 667 (53%) were referred on the 2WP and 604 (47%) on the 6WP. 698 (55%) were diagnosed with HF (369 HF with reduced ejection fraction) and 566 (45%) as not HF (NHF). 1-year mortality was 10% (n=129) and hospitalisation was 33% (n=413). Patients on the 2WP had higher mortality and hospitalisation rates than those on the 6WP, 14% vs 6% (p<0.001) and 38% vs 27% (p<0.001), respectively. All-cause mortality (11% vs 9%; p=0.306) and hospitalisation rates (35% vs 29%; p=0.128) did not differ between HF and NHF patients, respectively. CONCLUSIONS: Outcomes using the NICE approach of short waiting time targets for specialist assessment of patients with suspected HF and raised NTproBNP are not known. The model identifies an elderly population a high proportion of whom have HF. Irrespective of diagnosis, patients have high rates of adverse outcomes. These contemporary real-world data provide a platform for discussions with patients and shaping HF services.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Zheng A, Cowan E, Mach L, et al. Characteristics and outcomes of patients with suspected heart failure referred in line with National Institute for Health and Care Excellence guidance. Heart. 2020. PMID: 32690621. doi:10.1136/heartjnl-2019-316511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。